338 related articles for article (PubMed ID: 27748765)
21. Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance.
Martin LA; Ribas R; Simigdala N; Schuster E; Pancholi S; Tenev T; Gellert P; Buluwela L; Harrod A; Thornhill A; Nikitorowicz-Buniak J; Bhamra A; Turgeon MO; Poulogiannis G; Gao Q; Martins V; Hills M; Garcia-Murillas I; Fribbens C; Patani N; Li Z; Sikora MJ; Turner N; Zwart W; Oesterreich S; Carroll J; Ali S; Dowsett M
Nat Commun; 2017 Nov; 8(1):1865. PubMed ID: 29192207
[TBL] [Abstract][Full Text] [Related]
22. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer.
Brett JO; Spring LM; Bardia A; Wander SA
Breast Cancer Res; 2021 Aug; 23(1):85. PubMed ID: 34392831
[TBL] [Abstract][Full Text] [Related]
23. Estrogen receptor-alpha phosphorylated at Ser118 is present at the promoters of estrogen-regulated genes and is not altered due to HER-2 overexpression.
Weitsman GE; Li L; Skliris GP; Davie JR; Ung K; Niu Y; Curtis-Snell L; Tomes L; Watson PH; Murphy LC
Cancer Res; 2006 Oct; 66(20):10162-70. PubMed ID: 17047081
[TBL] [Abstract][Full Text] [Related]
24. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
[TBL] [Abstract][Full Text] [Related]
25. ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling.
Gelsomino L; Gu G; Rechoum Y; Beyer AR; Pejerrey SM; Tsimelzon A; Wang T; Huffman K; Ludlow A; Andò S; Fuqua SAW
Breast Cancer Res Treat; 2016 Jun; 157(2):253-265. PubMed ID: 27178332
[TBL] [Abstract][Full Text] [Related]
26. The estrogen receptor-alpha S118P variant does not affect breast cancer incidence or response to endocrine therapies.
Button B; Croessmann S; Chu D; Rosen DM; Zabransky DJ; Dalton WB; Cravero K; Kyker-Snowman K; Waters I; Karthikeyan S; Christenson ES; Donaldson J; Hunter T; Dennison L; Ramin C; May B; Roden R; Petry D; Armstrong DK; Visvanathan K; Park BH
Breast Cancer Res Treat; 2019 Apr; 174(2):401-412. PubMed ID: 30560461
[TBL] [Abstract][Full Text] [Related]
27. Mutations in the estrogen receptor alpha hormone binding domain promote stem cell phenotype through notch activation in breast cancer cell lines.
Gelsomino L; Panza S; Giordano C; Barone I; Gu G; Spina E; Catalano S; Fuqua S; Andò S
Cancer Lett; 2018 Aug; 428():12-20. PubMed ID: 29702197
[TBL] [Abstract][Full Text] [Related]
28. Activating
Toy W; Weir H; Razavi P; Lawson M; Goeppert AU; Mazzola AM; Smith A; Wilson J; Morrow C; Wong WL; De Stanchina E; Carlson KE; Martin TS; Uddin S; Li Z; Fanning S; Katzenellenbogen JA; Greene G; Baselga J; Chandarlapaty S
Cancer Discov; 2017 Mar; 7(3):277-287. PubMed ID: 27986707
[TBL] [Abstract][Full Text] [Related]
29. RRM2 and CDC6 are novel effectors of XBP1-mediated endocrine resistance and predictive markers of tamoxifen sensitivity.
Barua D; Sultana A; Islam MN; Cox F; Gupta A; Gupta S
BMC Cancer; 2023 Mar; 23(1):288. PubMed ID: 36997866
[TBL] [Abstract][Full Text] [Related]
30. Epidermal growth factor receptor signalling in human breast cancer cells operates parallel to estrogen receptor α signalling and results in tamoxifen insensitive proliferation.
Moerkens M; Zhang Y; Wester L; van de Water B; Meerman JH
BMC Cancer; 2014 Apr; 14():283. PubMed ID: 24758408
[TBL] [Abstract][Full Text] [Related]
31. GLL398, an oral selective estrogen receptor degrader (SERD), blocks tumor growth in xenograft breast cancer models.
Guo S; Zhang C; Mottamal M; Hossain A; Liu J; Wang G
Breast Cancer Res Treat; 2020 Apr; 180(2):359-368. PubMed ID: 32030569
[TBL] [Abstract][Full Text] [Related]
32. Estrogen receptor-α variant, ER-α36, is involved in tamoxifen resistance and estrogen hypersensitivity.
Zhang X; Wang ZY
Endocrinology; 2013 Jun; 154(6):1990-8. PubMed ID: 23546601
[TBL] [Abstract][Full Text] [Related]
33. G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer.
Andreano KJ; Wardell SE; Baker JG; Desautels TK; Baldi R; Chao CA; Heetderks KA; Bae Y; Xiong R; Tonetti DA; Gutgesell LM; Zhao J; Sorrentino JA; Thompson DA; Bisi JE; Strum JC; Thatcher GRJ; Norris JD
Breast Cancer Res Treat; 2020 Apr; 180(3):635-646. PubMed ID: 32130619
[TBL] [Abstract][Full Text] [Related]
34. Anterior gradient-2 plays a critical role in breast cancer cell growth and survival by modulating cyclin D1, estrogen receptor-alpha and survivin.
Vanderlaag KE; Hudak S; Bald L; Fayadat-Dilman L; Sathe M; Grein J; Janatpour MJ
Breast Cancer Res; 2010; 12(3):R32. PubMed ID: 20525379
[TBL] [Abstract][Full Text] [Related]
35. Proteomic profiling reveals that ESR1 mutations enhance cyclin-dependent kinase signaling.
De Marchi T; Lai CF; Simmons GM; Goldsbrough I; Harrod A; Lam T; Buluwela L; Kjellström S; Brueffer C; Saal LH; Malmström J; Ali S; Niméus E
Sci Rep; 2024 Mar; 14(1):6873. PubMed ID: 38519482
[TBL] [Abstract][Full Text] [Related]
36. Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.
Guest SK; Ribas R; Pancholi S; Nikitorowicz-Buniak J; Simigdala N; Dowsett M; Johnston SR; Martin LA
PLoS One; 2016; 11(6):e0157397. PubMed ID: 27308830
[TBL] [Abstract][Full Text] [Related]
37. Benzothiophenone Derivatives Targeting Mutant Forms of Estrogen Receptor-α in Hormone-Resistant Breast Cancers.
Singh K; Munuganti RSN; Lallous N; Dalal K; Yoon JS; Sharma A; Yamazaki T; Cherkasov A; Rennie PS
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29462880
[TBL] [Abstract][Full Text] [Related]
38. Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in
Hosfield DJ; Weber S; Li NS; Sauvage M; Joiner CF; Hancock GR; Sullivan EA; Ndukwe E; Han R; Cush S; Lainé M; Mader SC; Greene GL; Fanning SW
Elife; 2022 May; 11():. PubMed ID: 35575456
[TBL] [Abstract][Full Text] [Related]
39. Targeting ESR1 mutation-induced transcriptional addiction in breast cancer with BET inhibition.
Udden SN; Wang Q; Kumar S; Malladi VS; Wu SY; Wei S; Posner BA; Geboers S; Williams NS; Liu Y; Sharma JK; Mani RS; Malladi S; Parra K; Hofstad M; Raj GV; Larios JM; Jagsi R; Wicha MS; Park BH; Gupta GP; Chinnaiyan AM; Chiang CM; Alluri PG
JCI Insight; 2022 Sep; 7(17):. PubMed ID: 35881485
[TBL] [Abstract][Full Text] [Related]
40. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A
Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
